Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma
RESEARCH TRIANGLE PARK, NC – JANUARY 27, 2015 – Envisia Therapeutics today announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. ENV515is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particleformulation of a prostaglandin analog, travoprost, with the potential forsustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offersthe potential to significantly address the poor compliance that exists among glaucoma patients today to limit disease progression and vision loss.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.